Cargando...
Sacubitril/valsartan in heart failure: latest evidence and place in therapy
Despite significant therapeutic advances, patients with chronic heart failure (HF) remain at high risk for HF progression and death. Sacubitril/valsartan (previously known as LCZ696) is a first-in-class medicine that contains a neprilysin (NEP) inhibitor (sacubitril) and an angiotensin II (Ang-II) r...
Gardado en:
| Publicado en: | Ther Adv Chronic Dis |
|---|---|
| Autor Principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
SAGE Publications
2016
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5076745/ https://ncbi.nlm.nih.gov/pubmed/27803793 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040622316665350 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|